Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE for HCC with High Preoperative CTC
NCT02631499Phase 4Unknown
- Sponsor
- Fudan University
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fudan University. Primary endpoint: Early recurrence rates at 1 year. Status: unknown.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02631499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631499.